144 related articles for article (PubMed ID: 31903940)
1. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
Romagné F
Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
[No Abstract] [Full Text] [Related]
2. [Description of the French players from Avenir's investment program: the role of MabDesign].
Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
[No Abstract] [Full Text] [Related]
3. [Players from the program "Investments for the Future": MAbImprove MabEx].
Larivière M; Pèlegrin A; Martineau P; Watier H
Med Sci (Paris); 2019 Dec; 35(12):1204-1205. PubMed ID: 31903941
[No Abstract] [Full Text] [Related]
4. [Developability assessment with case studies highlighting the decision taking].
Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
[TBL] [Abstract][Full Text] [Related]
5. [The long path (s) of placing medicines on the market].
Duguet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
[No Abstract] [Full Text] [Related]
6. [Patentability of an antibody: evolution of rules and practices and prospects].
Collin M; Davison S
Med Sci (Paris); 2019 Dec; 35(12):1175-1181. PubMed ID: 31903934
[TBL] [Abstract][Full Text] [Related]
7. [The Antibody Club of the French Society of Immunology: structuring the assets of French research].
Larivière M; Monteiro R
Med Sci (Paris); 2019 Dec; 35(12):1206-1207. PubMed ID: 31903942
[No Abstract] [Full Text] [Related]
8. APS AAMC CFAS report.
Levitzky M
Physiologist; 2014 Sep; 57(5):203-4. PubMed ID: 25322526
[No Abstract] [Full Text] [Related]
9. Dissecting monoclonal antibody mega-deals.
Villiger R; Bogdan B
MAbs; 2009; 1(2):172-8. PubMed ID: 20061828
[TBL] [Abstract][Full Text] [Related]
10. [Developability assessment].
Dumas J; Huille S; Prades C
Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
[TBL] [Abstract][Full Text] [Related]
11. Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6
Martineau P; Watier H; Pèlegrin A; Turtoi A
MAbs; 2019 Jul; 11(5):812-825. PubMed ID: 31043141
[TBL] [Abstract][Full Text] [Related]
12. What's fueling the biotech engine-2007.
Aggarwal S
Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
[No Abstract] [Full Text] [Related]
13. Introducing: Capstone Articles.
Hewitt SM
J Histochem Cytochem; 2020 Jan; 68(1):73. PubMed ID: 31870240
[No Abstract] [Full Text] [Related]
14. [MAbs: the history of a basic research or the curiosity as a source of wealth].
Diallo BK; Riffard C; Le Gouge K; Teillaud JL
Med Sci (Paris); 2019 Dec; 35(12):926-936. PubMed ID: 31903896
[TBL] [Abstract][Full Text] [Related]
15. Future trends in outsourcing: a summary of the Bioanalysis Zone Survey.
Craddock A; Nadarajah S
Bioanalysis; 2017 Aug; 9(15):1127-1129. PubMed ID: 28766363
[No Abstract] [Full Text] [Related]
16. Senator asks psychiatrists' association about drug company funding.
Tanne JH
BMJ; 2008 Jul; 337():a929. PubMed ID: 18644779
[No Abstract] [Full Text] [Related]
17. Funding, conflicts, and paradigms.
Gelenberg AJ
J Clin Psychiatry; 2005 May; 66(5):554. PubMed ID: 15889939
[No Abstract] [Full Text] [Related]
18. Proceedings: the SEED grant program: a brief synopsis of the outcomes and impact of CIRM's first research initiative.
Shepard KA
Stem Cells Transl Med; 2015 Mar; 4(3):211-6. PubMed ID: 25646528
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the Crisis of Clinical Research.
Fava GA; Cosci F; Tomba E
Psychother Psychosom; 2018; 87(1):1-4. PubMed ID: 29306948
[No Abstract] [Full Text] [Related]
20. [Significant target misidentification].
Jordan B
Med Sci (Paris); 2020 Jan; 36(1):87-89. PubMed ID: 32014106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
